Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Trading Update and Notice of Results

Cyprotex PLC ('Cyprotex' or 'the Company')

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, announces a trading update on its performance in the calendar year ending 31 December 2009.

Following the Company's announcement on 20 November 2009, the Company confirms a solid level of activity in the months of November and December 2009, and as a result the Directors expect to report full year 2009 results to be in line with market expectations.

Cyprotex expects to report its final year end results to December 2009 on 17 March 2010.

For further information:

Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Noble & Company
John Llewellyn-Lloyd
Sam Reynolds
Tel: +44 (0) 20 7763 2200
sam.reynolds@noblegp.com
www.noblegp.com

Financial Dynamics
Ben Brewerton / Ben Atwell / John Dineen
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close